



DEC 21 2006

12 26-06

IFW
PTO/SB/21 (08-03)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/724,288
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1649
		Examiner Name	Ballard, Kimberly A.
Total Number of Pages in This Submission	18	Attorney Docket Number	15270J-004765US

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form (1 page, submitted in duplicate)	<input type="checkbox"/> Drawings Sheets	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	1. Return Receipt Postcard
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (8 pgs) with PTO/SB/08A (2 pgs) and SB/08B (4 pgs) Forms and *copies of reference nos. 739, 741-744, 749-757, 759, 765-769, 772-775, 786-794, 796-803, 806-818, and 820-827	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	The Commissioner is authorized to charge any additional fees to Deposit Account 19-4880.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	*Not included in "Total Number of Pages in This Submission"	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Rosemarie L. Celli	Reg. No. 42,397
Signature		
Date	December 21, 2006	

CERTIFICATE OF MAILING

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited on December 21, 2006 with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee," mailing label No. EV 749 121 034 US addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Typed or printed name	Loreta Villabrilie	
Signature		Date
	12/21/06	



Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL For FY 2005

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) **180**

Complete if Known

Application Number	09/724,288
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Examiner Name	Ballard, Kimberly A.
Art Unit	1649
Attorney Docket No.	15270J-004765US

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order None Other (please identify): _____

Deposit Account Deposit Account Number: 19-4880 Deposit Account Name: Sughrue Mion, PLLC

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee

Charge any additional fee(s) or underpayments of fee(s) Credit any overpayments

under 37 CFR 1.16 and 1.17

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

<u>Application Type</u>	<u>FILING FEES</u>		<u>SEARCH FEES</u>		<u>EXAMINATION FEES</u>		<u>Fees Paid (\$)</u>
	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>	
Utility							
Design							
Plant							
Reissue							
Provisional							

2. EXCESS CLAIM FEESFee Description

Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent

Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent

Multiple dependent claims

<u>Total Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	<u>Multiple Dependent Claims</u>	
	-20 or HP =	x	=	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
HP = highest number of total claims paid for, if greater than 20					

<u>Indep. Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	<u>Multiple Dependent Claims</u>	
	-3 or HP =	x	=	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
HP = highest number of independent claims paid for, if greater than 3					

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<u>Total Sheets</u>	<u>Extra Sheets</u>	<u>Number of each additional 50 or fraction thereof</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
- 100 =	/ 50 =	(round up to a whole number) x	=	

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Other: 1806 1.17(p) Submission of an Information Disclosure Statement

\$180

SUBMITTED BY

Signature 	Registration No. (Attorney/Agent) 42,397	Telephone 650-625-8100
Name (Print/Type) <u>Rosemarie L. Celli</u>		Date <u>Dec. 21, 2006</u>



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: SCHENK, Dale B.

Docket No: 15270J-004765US

Appln. No.: 09/724,288

Group Art Unit: 1649

Confirmation No.: 9431

Examiner: Ballard, Kimberly A.

Filed: November 28, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited on December 21, 2006 with the United States Postal Service in an envelope as "Express Mail Post Office To Addressee," mailing label No. EV 749 121 034 US addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

12/21/06
Date

Loreta Villabrine
Loreta Villabrine

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of references 739, 741-744, 749-757, 759, 765-769, 772-775, 786-794, 796-803, 806-818, and 820-827 are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites commonly owned copending applications directed to related subject matter:

Applicant also cites the following copending applications which are directed to related subject matter and are commonly owned or under an assignment obligation:

09/201,430 filed 11/30/98; issued as U.S. 6,787,523 on 09/07/04;

09/724,477 filed 11/28/00; issued as U.S. 6,787,143 on 09/07/04;

Application No. 09/724,288
Supplemental Information Disclosure Statement filed December 21, 2006

09/723,927 filed 11/28/00; issued as U.S. 6,787,138 on 09/07/04;
09/723,762 filed 11/28/00; issued as U.S. 6,787,144 on 09/07/04 ;
09/724,102 filed 11/28/00; issued as U.S. 6,787,139 on 09/07/04;
09/724,489 filed 11/28/00; issued as U.S. 6,787,140 on 09/07/04;
10/816,022 filed 03/31/04; issued as U.S. 6,866,850 on 03/15/05;
10/816,529 filed 03/31/04; issued as U.S. 6,818,218 on 11/16/04;
10/815,391 filed 03/31/04; issued as U.S. 6,866,849 on 03/15/05;
10/934,818 filed 09/02/04;
11/108,102 filed 04/15/05;
11/245,524 filed 10/07/05;
10/934,609 filed 09/02/04; issued as U.S. 6,946,135 on 09/20/2005;
11/245,916 filed 10/7/05;
10/933,559 filed 09/02/04; issued as U.S. 6,972,127 on 12/06/05;
10/815,353 filed 03/31/04; issued as U.S. 6,808,712 on 10/26/04;
10/816,380 filed 03/31/04; issued as US 7,014,855 on 03/21/06;
10/815,404 filed 03/31/04; issued as U.S. 6,982,084 on 01/03/06;
10/884,892 filed 07/01/04; issued as U.S. 6,962,707 on 11/08/05;
09/322,289 filed 05/28/99;
09/724,319 filed 11/27/00; Appeal Brief filed 10/10/06
09/723,384 filed 11/27/00; issued as U.S. 6,710,226 on 03/23/04;
10/429,216 filed 05/30/03;
10/828,548 filed 04/19/04;
10/923,471 filed 08/20/04;

Application No. 09/724,288
Supplemental Information Disclosure Statement filed December 21, 2006

10/923,474 filed 08/20/04;
10/928,926 filed 08/27/04;
10/923,605 filed 08/20/04;
10/923,469 filed 08/20/04;
09/724,940 filed 11/28/00; issued as U.S. 6,905,686 on 06/14/05;
09/724,961 filed 11/28/00; issued as U.S. 6,743,427 on 6/1/04;
11/058,757 filed 02/14/05;
09/580,018 filed 05/26/00; issued as U.S. 6,761,888 on 07/13/04;
09/724,552 filed 11/28/00; issued as U.S. 6,750,324 on 6/15/04;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00; issued as U.S. 6,787,637 on 09/07/04;
09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
10/890,000 filed 07/12/04;
10/890,070 filed 07/12/04;
10/890,071 filed 07/12/04;
09/723,765 filed 11/28/00; Appeal Brief filed 11/10/05;
09/724,567 filed 11/28/00; issued as U.S. 6,890,535 on 05/10/05;
09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00; issued as U.S. 6,875,434 on 04/05/05;
09/724,570 filed 11/28/00; issued as U.S. 6,936,246 on 08/30/05; and
09/979,952 filed 04/09/02 (U.S. National Stage of PCT/US00/15239 filed 06/01/00); issued as U.S. 6,913,745 on 07/05/05.

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01; issue fee paid 08/11/06

10/789,273 filed 2/27/04;

10/232,030 filed 08/30/02;

10/388,389 filed 03/12/03; issue fee paid 08/31/06

10/703,713 filed 11/07/03;

10/704,070 filed 11/07/03;

11/396,417 filed 03/30/06;

10/388,214 filed 03/12/03;

10/858,855 filed 06/01/04;

10/771,174 filed 02/04/04;

11/260,047 filed 10/26/05;

11/304,986 filed 12/15/05;

11/305,889 filed 12/15/05;

11/305,899 filed 12/15/05;

11/303,478 filed 12/15/05;

11/304,072 filed 12/15/05;

60/736,119 filed 11/10/05;

60/735,687 filed 11/10/05;

10/544,093 filed 08/01/05 (U.S. National Stage of PCT/US04/02856 filed 01/31/04);

11/342,353 filed 01/27/06;

10/583,503 filed 06/16/06

Application No. 09/724,288
Supplemental Information Disclosure Statement filed December 21, 2006

11/413,638 filed 04/28/06;
11/454,772 filed 06/16/06.
11/516,724 filed 09/05/06;
11/520,438 filed 09/12/06; and
60/793,014 filed 04/18/06.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
09/580,015 filed 05/26/00;
10/889,999 filed 04/12/04;
09/580,019 filed 05/26/00;
09/724,291 filed 11/28/00;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/980,568 filed 03/12/02 (U.S. National Stage of PCT/US00/15302 filed 06/01/00);
09/579,690 filed 05/26/00;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;

Application No. 09/724,288
Supplemental Information Disclosure Statement filed December 21, 2006

09/724,921 filed 11/28/00;
09/724,929 filed 11/28/00;
60/137,010 filed 06/01/99;
60/137,047 filed 06/01/99;
60/136,655 filed 05/28/99,
09/723,544 filed 11/28/00.
09/497,553 filed 02/03/00;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
09/979,701 filed 03/13/01 (U.S. National Stage of PCT/US00/14810 filed 05/26/00);
10/822,968 filed 04/12/04;
10/823,463 filed 04/12/04;
10/890,024 filed 04/12/04;
10/923,267 filed 08/20/04;
10/934,819 filed 09/02/04; and
11/396,391 filed 03/30/2006.

Applicant also cites the following abandoned applications directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;
60/444,150 filed 02/01/03;

Application No. 09/724,288
Supplemental Information Disclosure Statement filed December 21, 2006

60/616,474 filed 10/05/04;
60/530,481 filed 12/17/03;
60/474,654 filed 05/30/03;
60/363,751 filed 03/12/02.
60/622,525 filed 10/26/04;
60/636,684 filed 12/15/04;
60/636,842 filed 12/15/04;
60/637,253 filed 12/16/04;
60/636,810 filed 12/15/04;
60/637,138 filed 12/16/04;
60/636,776 filed 12/15/04;
60/636,687 filed 12/15/04;
60/736,045 filed 11/10/05;
60/691,821 filed 06/17/05; and
60/648,631 filed 01/28/05.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.

Application No. 09/724,288

Supplemental Information Disclosure Statement filed December 21, 2006

Applicant understands the Examiner can access papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner has difficulty obtaining papers from that source he or she are invited to call the undersigned who will be happy to supply them.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 19-4880. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Registration No. 42,397

SUGHRUE MION, PLLC
Telephone: (650) 625-8100
Facsimile: (650) 625-8110

MOUNTAIN VIEW OFFICE

23493

CUSTOMER NUMBER

Date: December 21, 2006

RLC/JEO

51170_1.DOC

60814886 v1



DEC 21 2006

PTO/SB/08A (08-03)

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/724,288
Sheet	1	of	6	Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
				Attorney Docket Number	15270J-004765US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	785	2005/0249725 A1	11-10-2005	Schenk et al.	
	758	2005/0169925 A1	08-04-2005	Bardroff et al.	
	784	2005/0118651 A1	06-02-2005	Basi et al.	
	805	2004/0197324 A1	10-07-2004	Jun et al.	
	783	2004/0087777 A1	05-06-2004	Basi et al.	
	782	2004/0082762 A1	04-29-2004	Basi et al.	
	804	2003/0202972 A1	10-30-2003	James et al.	
	748	6,610,493	08-26-2003	Citron et al.	
	776	6,372,716	04-16-2002	Bush et al.	
	777	6,270,757	08-07-2001	Warne	
	778	6,267,958	07-31-2001	Andya et al.	
	795	6,210,671	04-03-2001	Co	
	747	6,175,057	01-16-2001	Mucke et al.	
	771	5,837,268	11-17-1998	Potter et al.	
	779	5,770,700	06-23-1998	Webb et al.	
	780	5,744,132	04-28-1998	Warne et al.	
	770	5,733,548	03-31-1998	Restifo et al.	
	764	5,601,827	02-11-1997	Collier et al.	
	781	5,385,887	01-31-1995	Yim et al.	
	819	5,227,159	07-13-1993	Miller	
	740	4,883,666	11-28-1989	Sabel et al.	
	763	60/067,740	filed 12-02-1997	Schenk	
	760	60/067,219	filed 12-03-1997	Weiner et al.	
	761	60/079,697	filed 03-27-1998	Weiner et al.	
	762	60/080,970	filed 01-11-1999	Schenk	

Examiner Signature	Date Considered
--------------------	-----------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60814886 / 51175-1

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/724,288
Sheet	2	of	6	Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
				Attorney Docket Number	15270J-004765US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	786	EP	758 901	B1	02-26-1997			
	787	EP	758 248	B1	02-19-1997			
	802	EP	597 101	A1	05-18-1994			
	820	EP	285 159	A1	10-05-1988			
	757	WO	04/108895	A2, A3	12-16-2004			
	797	WO	04/055164	A2	07-01-2004			
	796	WO	03/105894	A1	12-24-2003			
	799	WO	03/39485	A2	05-15-2003			
	756	WO	03/16467	A2, A3	02-27-2003			
	788	WO	03/15691	A2	02-27-2003			
	803	WO	03/16466	A2	02-27-2003			
	798	WO	03/09817	A2	02-06-2003			
	827	WO	02/96937	A2	12-05-2002			
	789	WO	01/05355	A2	01-25-2001			
	772	WO	99/10008	A1	03-04-1999			
	813	WO	97/03192	A3	01-30-1997			
	814	WO	94/00153	A1	01-06-1994			
	821	WO	91/16928	A1	11-14-1991			

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/724,288
(use as many sheets as necessary)				Filing Date	November 28, 2000
Sheet	3	of	6	First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
				Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	773	ALBERTS ET AL., <i>Molecular Biology of the Cell</i> , 2nd Edition, pages 266-267, Garland Publishing Inc., New York (1989).		
	790	BALES et al., "Administration of an Anti-A β Fab Fragment to APP ^{V717F} Transgenic Mice Reduces Neuritic Plaque," Abstract P\$-396, Page S587, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based		
	750	BICKEL et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against β A4 Protein: A Potential Probe for Alzheimer's Disease," <i>Bioconjugate Chem.</i> , 5:119-125 (1994).		
	754	BLASBERG et al., "Regional Localization of Glioma-associated Antigen Defined by Monoclonal Antibody 81C6 <i>in Vivo</i> : Kinetics and Implications for Diagnosis and Therapy," <i>Cancer Research</i> , 47:4432-4443 (1987).		
	824	BROOKMEYER et al., "Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset," <i>Am. J. Public Health</i> , 88:1337-1342 (1998).		
	791	BUSSIERE et al., "Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive A β Immunotherapy on Their Clearance," <i>Am. J. Pathology</i> , 165(3):987-995 (2004).		
	823	CASSELL et al., "Demography and Epidemiology of Age-Associated Neuronal Impairment," chapter 4, pages 31-50 from <i>Functional Neurobiology of Aging</i> , Hof et al., eds., Academic Press (2001).		
	766	COICO et al., <i>Immunology A Short Course</i> , Fifth Edition, pages 18-24 (2003).		
	769	DAVIS, S. S., "Nasal Vaccines," <i>Advanced Drug Delivery Reviews</i> , 51:21-42 (2001).		
	817	DU et al., " α_2 -Macroglobulin as a β -Amyloid Peptide-Binding Plasma Protein," <i>J. Neurochemistry</i> , 69(1):299-305 (1997).		
	811	European Search Report of 5/22/06 for European Application 06075704.4-2107.		
	812	European Search Report of 5/22/06 for European Application 06075479.3-2107.		
	807	HARA et al., "Development of a safe oral A β vaccine using recombinant adeno-associated virus vector for Alzheimer's disease," <i>J. Alzheimer's Disease</i> , 6:483-488 (2004).		
	741	HIRSCHFIELD et al., "Amyloidosis: new strategies for treatment," <i>Int. J. Biochem. & Cell Biol.</i> , 35:1608-1613 (2003).		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	4	of	6	Application Number	09/724,288
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
				Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	792	KAJKOWSKI et al., "β-Amyloid Peptide-induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation Module," <i>J. Biol. Chem.</i> , 276(22):18748-18756 (2001).		
	794	KOFLER et al., "Immunoglobulin κ Light Chain Variable Region Gene Complex Organization and Immunoglobulin Genes Encoding Anti-DNA Autoantibodies in Lupus Mice," <i>J. Clin. Invest.</i> , 82:852-860 (1988).		
	826	KUBY, J., eds., page 123 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).		
	816	LaDu et al., "Isoform-specific Binding of Apolipoprotein E to β-Amyloid," <i>J. Biol. Chem.</i> , 269(38):23403-23406 (1994).		
	755	LAVIE et al., "EFRH-Phage Immunization of Alzheimer's Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials," <i>J. Molecular Neuroscience</i> , 24:105-113 (2004).		
	743	LICASTRO et al., "Is immunotherapy an effective treatment for Alzheimer's disease?," <i>Immunity & Aging</i> , 1:1-2 (2004).		
	742	MANOJ et al., "Approaches to Enhance the Efficacy of DNA Vaccines," <i>Critical Rev. Clin. Lab. Sci.</i> , 41(1):1-39 (2004).		
	744	MAROTTA et al., "Overexpression of amyloid precursor protein A4 (β-amyloid) immunoreactivity in genetically transformed cells: Implications for a cellular model of Alzheimer amyloidosis," <i>PNAS</i> , 86:337-341 (1989).		
	822	Merriam-Webster online medical dictionary, entry for "cure", accessed September 5, 2006.		
	808	OKURA et al., "Nonviral Aβ DNA vaccine therapy against Alzheimer's disease: Long-term effect and safety," <i>PNAS</i> , 103(25):9619-9624 (2006).		
	806	PCT Search Report of 8/11/06 for application PCT/US2006/002837.		
	774	PEETERS et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," <i>J. Immunological Methods</i> , 120:133-143 (1989).		
	751	PROBERT et al., "Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α," <i>PNAS</i> , 92:11294-11298 (1995).		
	809	QU et al., "Aβ ₄₂ gene vaccination reduces brain amyloid plaque burden in transgenic mice," <i>J. Neurological Sciences</i> , 244:151-158 (2006).		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	09/724,288
(use as many sheets as necessary)				<i>Filing Date</i>	November 28, 2000
				<i>First Named Inventor</i>	Schenk, Dale B.
				<i>Art Unit</i>	1649
				<i>Examiner Name</i>	Kimberly A. Ballard
Sheet	5	of	6	<i>Attorney Docket Number</i>	15270J-004765US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	759	SCHENK et al., "Current progress in beta-amyloid immunotherapy," <u>Curr. Opin. Immunology</u> , 16(5):599-606 (2004).		
	768	SCHMITT et al., "Interactions of the alzheimer β amyloid fragment ₍₂₅₋₃₅₎ with peripheral blood dendritic cells," <u>Mechanisms of Ageing and Development</u> , 94:223-232 (1997).		
	818	SHINKAI et al., "Amyloid β -Proteins 1-40 and 1-42(43) in the Soluble Fraction of Extra- and Intracranial Blood Vessels," <u>Ann. Neurol.</u> , 38:421-428 (1995).		
	767	TRIEB et al., "APP Peptides Stimulate Lymphocyte Proliferation in Normals, But Not in Patients With Alzheimer's Disease," <u>Neurobiology of Aging</u> , 17(4):541-547 (1996).		
	815	URMONEIT et al., "Cerebrovascular Smooth Muscle CElls Internalize Alzheimer Amyloid Beta Protein via a Lipoprotein Pathway: Implications for Cerebral Amyloid Angiopathy," <u>Laboratory Investigation</u> , 77(2):157-166 (1997).		
	775	VAN DEN DOBBELSTEEN et al., "Characteristics of Immune Responses to Native and Protein Conjugated Pneumococcal Polysaccharide Type 14," <u>Scand. J. Immunol.</u> , 41:273-280 (1995).		
	800	VIDANOVIC et al., "Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation," <u>DIE PHARMAZIE</u> , 58(6):399-404 (2003).		
	801	WANG, W., "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <u>Int. J. Pharmaceutics</u> , 185(2):129-188 (1999).		
	765	WEINER, H. L., "Oral tolerance: immune mechanisms and treatment of autoimmune diseases," <u>Immunology Today</u> , 18:335-343 (1997).		
	739	WEINREB et al., "NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded," <u>Biochemistry</u> , 35(43):13709-13715 (1996).		
	749	Wikipedia definition of "epitope" printed from internet on 4/26/06.		
	752	Wikipedia definition of "antigen" printed from internet on 4/26/06.		
	753	Wikipedia definition of "route of administration including parenteral" printed from internet on 4/26/06.		
	793	ZAMEER et al., "Single Chain Fv Antibodies against 25-35 Peptide Fragment of Amyloid- β : Potential Therapeutic for Alzheimer's Disease," Abstract P4-420, Page S593, presented at Poster Session P4:Therapeutics and Therapeutic Strategies-Therapeutic Strateies, Amyloid-Based		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	09/724,288
				<i>Filing Date</i>	November 28, 2000
				<i>First Named Inventor</i>	Schenk, Dale B.
				<i>Art Unit</i>	1649
				<i>Examiner Name</i>	Kimberly A. Ballard
Sheet	6	of	6	<i>Attorney Docket Number</i>	15270J-004765US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	810	ZHANG et al., "A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β -amyloid plaques in a mouse model of Alzheimer's disease," <u>Neurobiology of Disease</u> , 14:365-379 (2003).		
	825	ZHANG et al., "Specialized Applications, Purification of Recombinant Proteins and Study of Protein Interaction by Epitope Tagging," <u>Current Protocols in Mol. Biol.</u> , Supp 41, pages 10.15.1 through 10.15.9 (1998).		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.